Brexpiprazole is primarily used in the treatment of psychiatric conditions. It is approved as an adjunctive therapy for major depressive disorder (MDD) when standard antidepressants alone are insufficient. It is also approved for managing schizophrenia, helping to alleviate symptoms such as hallucinations, delusions, and disorganized thinking. Additionally, it is approved as adjunctive therapy with lithium or valproate for the maintenance treatment of bipolar I disorder. The medication works by modulating serotonin and dopamine activity in the brain, which helps stabilize mood and improve cognitive function. In clinical settings, it is valued for its relatively mild side effect profile compared to other antipsychotics, making it a preferred option for long-term treatment. Brexpiprazole is sometimes prescribed off-label for conditions like anxiety, though further research is needed to confirm its efficacy in these areas. Its use is typically monitored closely by healthcare providers to ensure optimal dosing and minimize potential adverse effects.